Oral cancer test SG-OCRA™
An innovative non-invasive test for the early detection of oral squamous cell carcinoma (OSCC) and high-grade dysplasia. The test is based on epigenetic DNA methylation analysis of oral mucosal cells collected with a special brush – no incisions, no pain, no stress.
Oral cancer is a common and dangerous disease that may cause no symptoms for a long time
Oral squamous cell carcinoma accounts for as much as 95% of all head and neck cancers, with around 750,000 new cases diagnosed worldwide each year. Due to late diagnosis, the five-year mortality rate reaches 50%.
The disease is most often detected at an advanced stage, which is why early detection is critical. This test enables timely identification of early changes and helps prevent a dangerous disease course.
How does the oral cancer test SG-OCRA™ work?
The test is designed for early detection of OSCC and high-grade dysplasia. It is based on epigenetic DNA methylation analysis performed using next-generation sequencing (NGS). The sample is collected from the oral mucosa using a special brush – the procedure is completely non-invasive and painless. By analysing DNA methylation in 13 specific genes, a patented algorithm calculates a risk score that helps determine whether the patient has OSCC or precancerous changes.
Based on epigenetic DNA methylation analysis
Analyses 13 clinically relevant genes
Sample collected with a simple brush from the oral mucosa
Risk score assessed using a patented diagnostic model
No biopsy, needles, or surgical intervention required
An early step to protect your health
Oral cancer often develops unnoticed, so early diagnosis can be decisive for survival. This test helps identify the earliest changes when the disease may still be fully treatable – without pain, surgery, or complex procedures.
Early cancer detection without discomfort
No needles or surgical intervention – sampling is done with a simple brush on the oral mucosa. Safe even for sensitive patients or those who avoid procedures.
High-accuracy epigenetic analysis
Next-generation sequencing (NGS) and methylation marker analysis can detect OSCC or precancerous changes even when there are no obvious symptoms yet.
The only test of its kind on the market
The test is based on patented technology (European patent EP3374527) and currently has no equivalents – an exceptional opportunity to use the most advanced diagnostics in everyday practice.
Suitable for risk groups and anyone with suspicious symptoms
Especially recommended for smokers, people who misuse alcohol, and those with HPV infection. Also relevant for anyone with common oral cancer signs (a non-healing sore, patches in the mouth, a lump in the cheek, etc.).
When and for whom is the test recommended?
For people with suspicious changes in the oral cavity
Sores on the oral mucosa, white or red patches, a lump, or numbness in the mouth area can be early signs of oral cancer – the test helps quickly and safely clarify the cause.
For smokers or frequent alcohol users
These habits significantly increase oral cancer risk, and regular screening can help detect disease at an early stage.
For individuals in the 50–60 age group
This is the most common age range for oral cancer diagnosis, although the trend is beginning to shift.
For younger patients without obvious risk factors
Cases are increasing among younger people without typical risk factors – so the test is also relevant if symptoms occur or if there is a family history of cancer.
Test reliability: accuracy and quality metrics
The oral cancer test is based on epigenetic DNA methylation analysis using next-generation sequencing and a patented algorithm. It enables accurate identification of patients with OSCC or high-grade dysplasia – even in early disease stages.
Analysis of 13 specific genes
Next-generation sequencing (NGS)
100% non-invasive sample collection
Early oral cancer detection – without pain or discomfort
Take the non-invasive test and find out whether oral changes may be associated with cancer or dysplasia.
For Specialists
All key information in one place – from the genes analysed to test accuracy and clinical value. This section is intended for specialists who want a detailed understanding of the test rationale, structure, and practical applications.
The test is based on quantitative epigenetic DNA methylation analysis performed using next-generation sequencing (NGS). Oral mucosal cells are collected with a special brush – this is completely non-invasive and does not cause patient discomfort.
The test analyses 13 clinically relevant genes associated with the development of OSCC and high-grade dysplasia. The data are evaluated using a patented diagnostic algorithm, which is used to calculate a risk score.
Intended for patients with suspected oral mucosal changes (leukoplakia, erythroplakia, chronic sores, etc.) and for higher-risk individuals (smokers, alcohol misuse, HPV). Can be used as an additional tool when deciding whether a biopsy is needed.
This is currently the only test of its kind on the market with no alternative methods. The technology is patented (European Patent No. EP3374527) and results are grounded in the latest advances in epigenetics.
Recommended for patients with persistent oral mucosal changes or symptoms potentially associated with OSCC. Also suitable for preventive screening in risk groups, including people without typical risk factors but with suspicious clinical signs.
